Cancun ... again, I would've loved tto hear about tthe partners that are "in discussion" ... Confidentiality Agreements

foundation for success clinically, and ptential markets, are looking more and more established, and closer to "proven"

Agree with SF ... tea leaves say buy out ... but when? ... would have to be soon, for the additional work to get accomplished. Excited about the FDA letter, obviously "breakthrough" status is being pursued, and the worst case "appears" to be a shorter bolt-on(s) with so much "work" already being done (P1, P2, P3) for potential buyers, good safety, additional IP, and patent protections ... 

Who wants this drug the most? When? At what price? What price is acceptable to the investors based on potential and risks?

dyodd